REPLIGEN CORP
Close on Oct 19, 2026
- Market cap
- $9.99B
- P/E (TTM)
- 205.2
- Dividend yield
- –
Earnings
Next report expected Oct 27, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 28, 2026 | Before market open | $204.00M | $0.09 | $0.54 |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | Before market open | $194.00M | $0.15 | $0.48 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 24, 2026 | Before market open | $198.00M | $0.23 | $0.49 |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 28, 2025 | Before market open | $189.00M | $0.26 | $0.46 |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 29, 2025 | Before market open | $182.00M | $0.26 | $0.37 |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 29, 2025 | Before market open | $169.00M | $0.10 | $0.39 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 20, 2025 | Before market open | $168.00M | $-0.60 | $0.44 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | $155.00M | $-0.01 | $0.43 |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 30, 2024 | Before market open | $154.00M | $0.06 | $0.33 |
| Q1 FY2024 Ended Mar 31, 2024 | May 1, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 21, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Jul 28, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDA Marginnon-GAAP | FY 2026 | 20.6% to 21% | New |
| Earnings Per Share - Dilutednon-GAAP | FY 2026 | $2.03 to $2.09 | New |
| Gross Marginnon-GAAP | FY 2026 | 53.7% to 54.2% | New |
| Income from Operationsnon-GAAP | FY 2026 | $128.00M to $134.00M | New |
| Operating Marginnon-GAAP | FY 2026 | 15.7% to 16% | New |
| Reported Growthnon-GAAP | FY 2026 | 10% to 13% growth | New |
| Organic Growthnon-GAAP | FY 2026 | 10.5% to 13.5% growth | Raised |
| Other Income (Expense)non-GAAP | FY 2026 | $19.00M | New |
| Tax Rate on Pre-Tax Incomenon-GAAP | FY 2026 | 22% | New |
| Net Incomenon-GAAP | FY 2026 | $115.50M to $118.50M | Raised |
| Total Reported Revenuenon-GAAP | FY 2026 | $813.00M to $835.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Repligen filed with the SEC
REPLIGEN COMPLETES ACQUISITION OF BIOLIFE SOLUTIONS
Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading
Material agreement · Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
July 22, 2026 Repligen to Acquire
Material agreement · Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Why is Repligen acquiring BioLife Solutions?
Material agreement · Results of operations · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
Results of operations · EX-99.1 to Form 8-K
REPLIGEN Executive chair tony hunt to retire; Dr. martin D. MadAus elected chair
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Repligen Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Repligen Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Repligen Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Repligen Reports Third Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Restatement Periods: Q1 2023 to Q2 2024 GAAP to Non-GAAP Reconciliations Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
September 18, 2024 8-K Supplement
Results of operations · Prior financials no longer reliable · Regulation FD disclosure · EX-99.1 to Form 8-K
Repligen Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
REPLIGEN ANNOUNCES CEO TRANSITION PLAN
Regulation FD disclosure · EX-99.1 to Form 8-K
Repligen Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Repligen Appoints Maggie A. Pax to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Repligen Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Re: Exchange and/or Subscription for Repligen Corporation Convertible Senior Notes due 2028
Unregistered share sale · Other events · EX-99.1 to Form 8-K
REPLIGEN ANNOUNCES PRIVATE CONVERTIBLE TRANSACTION OF $600 MILLION
Unregistered share sale · Other events · EX-99.2 to Form 8-K
Repligen Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
REPLIGEN ANNOUNCES AGREEMENT TO ACQUIRE
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
September 26, 2023 Repligen to Acquire
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Repligen Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
and Updates Full Year 2023 Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Repligen’s estimated financial results, future financial performance and other statements identified by words like “estimated,” “anticipated,” guidance, or “goal,” and similar expressions are forward-looking
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Repligen Reports Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Repligen Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Repligen Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Repligen Appoints Dr. Konstantin Konstantinov to Board of Directors
Executive or director change · Shareholder vote results · Other events · EX-99.1 to Form 8-K
Repligen Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Repligen Reports Fourth Quarter and Full Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
*Acquisition of BioFlex Solutions, LLC includes the company’s manufacturing arm, Newton T&M
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Repligen Reports Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K